ATE330632T1 - Selektion von fxr-rezeptormodulatoren - Google Patents
Selektion von fxr-rezeptormodulatorenInfo
- Publication number
- ATE330632T1 ATE330632T1 AT04075173T AT04075173T ATE330632T1 AT E330632 T1 ATE330632 T1 AT E330632T1 AT 04075173 T AT04075173 T AT 04075173T AT 04075173 T AT04075173 T AT 04075173T AT E330632 T1 ATE330632 T1 AT E330632T1
- Authority
- AT
- Austria
- Prior art keywords
- fxr
- selection
- receptor modulators
- methods
- fxr receptor
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004164 orphan nuclear receptors Human genes 0.000 abstract 1
- 108090000629 orphan nuclear receptors Proteins 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Vascular Medicine (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- High Energy & Nuclear Physics (AREA)
- Toxicology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12633499P | 1999-03-26 | 1999-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE330632T1 true ATE330632T1 (de) | 2006-07-15 |
Family
ID=22424256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04075173T ATE330632T1 (de) | 1999-03-26 | 2000-03-24 | Selektion von fxr-rezeptormodulatoren |
| AT00918345T ATE274921T1 (de) | 1999-03-26 | 2000-03-24 | Verfahren zur selektion von fxr- rezeptormodulatoren |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00918345T ATE274921T1 (de) | 1999-03-26 | 2000-03-24 | Verfahren zur selektion von fxr- rezeptormodulatoren |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1165135B1 (de) |
| JP (1) | JP2004510682A (de) |
| AT (2) | ATE330632T1 (de) |
| AU (1) | AU780658B2 (de) |
| CA (1) | CA2368234A1 (de) |
| DE (2) | DE60013417T2 (de) |
| WO (1) | WO2000057915A1 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2326850T3 (es) | 1998-12-23 | 2009-10-20 | Glaxo Group Limited | Ensayos para ligandos de receptores nucleares. |
| AU2002213893A1 (en) * | 2000-09-16 | 2002-03-26 | Lion Bioscience Ag | Nuclear receptor l66 and methods of use |
| FR2820435B1 (fr) * | 2001-02-05 | 2004-02-27 | Genfit S A | Procedes d'identification de composes modulant le transport inverse du cholesterol |
| ATE303399T1 (de) | 2001-03-12 | 2005-09-15 | Intercept Pharmaceuticals Inc | Steroide als agonisten für fxr |
| US7053076B2 (en) | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| AU2002351412B2 (en) | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
| US6696473B2 (en) | 2001-12-21 | 2004-02-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
| US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
| EP1572660B1 (de) | 2002-12-20 | 2011-01-26 | X-Ceptor Therapeutics, Inc. | Isochinolinonderivate und deren verwendung als medikamente |
| US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
| PL1734970T3 (pl) | 2004-03-12 | 2015-05-29 | Intercept Pharmaceuticals Inc | Leczenie zwłóknienia z zastosowaniem ligandów FXR |
| WO2005103283A1 (ja) * | 2004-04-23 | 2005-11-03 | Takeda Pharmaceutical Company Limited | 新規スクリーニング方法 |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| WO2007002563A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| JP5292310B2 (ja) | 2007-01-19 | 2013-09-18 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｔｇｒ５調節剤としての２３−置換胆汁酸およびその使用方法 |
| EA020310B1 (ru) | 2008-07-30 | 2014-10-30 | Интерсепт Фармасьютикалз, Инк. | Модуляторы рецептора tgr5 и их применение |
| ES2663948T3 (es) | 2008-11-19 | 2018-04-17 | Intercept Pharmaceuticals, Inc. | Moduladores de TGR5 y método de uso de los mismos |
| HRP20170194T1 (hr) | 2009-05-28 | 2017-05-19 | Exelixis Patent Company Llc | Lxr modulatori |
| AR088728A1 (es) | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
| AU2012311599B2 (en) * | 2011-09-19 | 2017-07-06 | Eth Zurich | Ror gamma modulators |
| AU2013274078A1 (en) | 2012-06-14 | 2015-01-29 | Ambrx, Inc. | Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides |
| PT3336097T (pt) | 2012-06-19 | 2020-10-29 | Intercept Pharmaceuticals Inc | Preparação da forma não cristalina de ácido obeticólico |
| US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
| EP2781217A1 (de) * | 2013-03-18 | 2014-09-24 | ETH Zurich | ROR-Gammamodulatoren |
| WO2018049362A1 (en) * | 2016-09-12 | 2018-03-15 | Massachusetts Institute Of Technology | Transcriptional sensor for bile acids in bacteroides thetaiotaomicron |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994018346A1 (en) * | 1993-02-05 | 1994-08-18 | The Board Of Regents Of The University Of Texas System | Cholesterol 7-alpha hydroxylase expression regulation |
| US5843474A (en) * | 1995-10-11 | 1998-12-01 | Reverse Transport Licensing & Consulting, Inc. | Method of dialysis treatment, and dialysis apparatus related thereto |
| AU2332497A (en) * | 1996-03-19 | 1997-10-10 | Salk Institute For Biological Studies, The | (in vitro) methods for identifying modulators of members of the steroid/thyroid superfamily of receptors |
| JPH11507246A (ja) * | 1996-03-20 | 1999-06-29 | ダイアックス コープ． | 巨大分子用アフィニティ・リガンドの設計 |
-
2000
- 2000-03-24 WO PCT/US2000/007836 patent/WO2000057915A1/en not_active Ceased
- 2000-03-24 EP EP00918345A patent/EP1165135B1/de not_active Expired - Lifetime
- 2000-03-24 JP JP2000607664A patent/JP2004510682A/ja active Pending
- 2000-03-24 DE DE60013417T patent/DE60013417T2/de not_active Expired - Fee Related
- 2000-03-24 AT AT04075173T patent/ATE330632T1/de not_active IP Right Cessation
- 2000-03-24 DE DE60029029T patent/DE60029029T2/de not_active Expired - Fee Related
- 2000-03-24 CA CA002368234A patent/CA2368234A1/en not_active Abandoned
- 2000-03-24 AU AU39173/00A patent/AU780658B2/en not_active Ceased
- 2000-03-24 AT AT00918345T patent/ATE274921T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60013417T2 (de) | 2005-09-15 |
| AU3917300A (en) | 2000-10-16 |
| ATE274921T1 (de) | 2004-09-15 |
| EP1165135A1 (de) | 2002-01-02 |
| DE60029029D1 (de) | 2006-08-03 |
| WO2000057915A1 (en) | 2000-10-05 |
| DE60029029T2 (de) | 2007-06-14 |
| DE60013417D1 (de) | 2004-10-07 |
| JP2004510682A (ja) | 2004-04-08 |
| AU780658B2 (en) | 2005-04-07 |
| CA2368234A1 (en) | 2000-10-05 |
| EP1165135B1 (de) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60029029D1 (de) | Selektion von FXR-Rezeptormodulatoren | |
| DE60336901D1 (de) | Chinazolinon modulatoren von nukleinrezeptoren | |
| WO2003030612A3 (en) | Methods for modulating activity of the fxr nuclear receptor | |
| DE69531403D1 (de) | Allosterische modulatoren des nmda-rezeptors | |
| ATE298248T1 (de) | T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung | |
| WO2003068944A3 (en) | METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α- | |
| NO20050717L (no) | Metode og sammensetninger for modulering av T hjelpe (TH) celleutvikling og funksjon | |
| ES2168650T3 (es) | Compuestos y metodos moduladores de receptores de androgenos. | |
| NO960767L (no) | Protocadherinproteiner og deres anvendelse | |
| MX339420B (es) | Compuestos para la modulacion de la actividad de ppar gamma. | |
| DE69835225D1 (de) | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen | |
| NO990086D0 (no) | Avkortete, oppl÷selige tumornekrosefaktorreseptorer av type I og type II | |
| NO980198L (no) | Modulatorer av funksjonen til FAS-reseptorer og andre proteiner | |
| DE69933653D1 (de) | Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen | |
| DK1200831T3 (da) | Modulatorisk bindingssted i kaliumkanaler til screening | |
| AU4981500A (en) | Cancer treatment with endothelin receptor antagonists | |
| WO2004039955A3 (en) | Modulators of angiogenesis and tumorigenesis | |
| IL124652A (en) | Screening assay for compounds stimulating somatostatin and insulin production | |
| WO2002044376A3 (en) | Modulation of gene expression using insulator binding proteins | |
| DE60033576D1 (de) | Methoden zum screening knochenmorphogenetishemimetika | |
| DE60210253D1 (de) | Verfahren zur identifizierung von modulatoren des cholesterinrückwärtstransportes | |
| ATE263373T1 (de) | Verfahren und zusammensetzungen zum screenen von modulatoren von sphingosinkinasen | |
| WO2002099438A3 (en) | Modulation of steroid hormone uptake | |
| DE69839265D1 (de) | Modulatoren der expression von morphogenen und deren identifizierungsverfahren | |
| WO2001092578A3 (en) | Reagents and methods for identifying and modulating expression of genes regulated by retinoids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |